Lower doses, same hope? new trial aims to tame myeloma with fewer side effects

NCT ID NCT05145400

Recruiting now Disease control Sponsor: UNC Lineberger Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tests a combination of three drugs—isatuximab, lenalidomide, and dexamethasone—at lower doses than usual for people newly diagnosed with multiple myeloma who are at high risk for side effects. The goal is to see if the treatment can still control the cancer while being easier to tolerate. About 50 participants will be enrolled, and the main measure of success is how many patients achieve at least a partial response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: isatuximab, lenalidomide, and dexamethasone
What this could lead to: If successful, this could show that lower doses of these drugs effectively control multiple myeloma while reducing harsh side effects for vulnerable patients.
What could go wrong: This is a small, early-phase trial with only 50 participants. Lower doses may not control the cancer as well, and side effects could still occur.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANCER MULTIPLE MYELOMA

Contacts and locations

Locations

Duke Comprehensive Cancer Center
RECRUITING

Durham, North Carolina, 27710, United States
Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Novant Health New Hanover Regional Medical Center
RECRUITING

Wilmington, North Carolina, 28401, United States
The Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.